Asian Growth Companies With Strong Insider Ownership April 2025

As global markets grapple with economic uncertainty and inflation concerns, the Asian market remains a focal point for investors seeking growth opportunities. In this environment, companies with strong insider ownership can be particularly appealing, as they often indicate alignment between management and shareholder interests.

Top 10 Growth Companies With High Insider Ownership In Asia

Click here to see the full list of 655 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

Jiangxi Rimag Group (SEHK:2522)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Jiangxi Rimag Group Co., Ltd. operates medical imaging centers in China with a market cap of HK$8.52 billion.

Operations: The company generates revenue primarily from its Medical Labs & Research segment, amounting to CN¥760.59 million.

Insider Ownership: 24.3%

Jiangxi Rimag Group is poised for significant growth, with revenue expected to increase by 24.8% annually, outpacing the Hong Kong market. Despite a recent net loss of CNY 45.92 million due to macroeconomic factors and listing expenses, the company is set to become profitable in three years. A strategic alliance with Xunfei Healthcare aims to enhance its smart healthcare offerings and expand market reach, potentially bolstering its position in the medical imaging industry.

• Delve into the full analysis future growth report here for a deeper understanding of Jiangxi Rimag Group.
• The analysis detailed in our Jiangxi Rimag Group valuation report hints at an inflated share price compared to its estimated value.

BrightGene Bio-Medical Technology (SHSE:688166)

Simply Wall St Growth Rating: ★★★★★☆

Overview: BrightGene Bio-Medical Technology Co., Ltd. is a pharmaceutical company involved in the research, development, manufacture, and commercialization of pharmaceutical products in China with a market cap of CN¥17.51 billion.

Operations: BrightGene Bio-Medical Technology Co., Ltd. generates revenue through its focus on the research, development, production, and marketing of pharmaceutical products within China.

Insider Ownership: 32.2%

BrightGene Bio-Medical Technology is expected to see robust growth, with earnings projected to rise 38.9% annually, surpassing the CN market's average. Revenue is also forecasted to grow significantly at 31.1% per year. Despite trading at a substantial discount to its estimated fair value, the company's financial position is challenged by inadequate operating cash flow coverage for debt. Recent earnings showed increased sales but slightly decreased net income compared to the previous year.

• Dive into the specifics of BrightGene Bio-Medical Technology here with our thorough growth forecast report.
• In light of our recent valuation report, it seems possible that BrightGene Bio-Medical Technology is trading beyond its estimated value.

Shenzhen New Industries Biomedical Engineering (SZSE:300832)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Shenzhen New Industries Biomedical Engineering Co., Ltd. focuses on the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals both in China and internationally, with a market cap of CN¥47.32 billion.

Operations: The company's revenue primarily comes from its in vitro diagnostic segment, which generated CN¥4.44 billion.

Insider Ownership: 21.8%

Shenzhen New Industries Biomedical Engineering is positioned for substantial growth, with revenue anticipated to increase by 20.5% annually, outpacing the broader CN market. Although earnings growth at 21% per year lags behind the market average, its forecasted high return on equity of 23.9% in three years is promising. The stock trades at a discount to fair value and offers good relative value compared to peers, despite an unstable dividend history and no recent insider trading activity reported.

• Take a closer look at Shenzhen New Industries Biomedical Engineering's potential here in our earnings growth report.
• In light of our recent valuation report, it seems possible that Shenzhen New Industries Biomedical Engineering is trading behind its estimated value.

Summing It All Up

• Unlock more gems! Our Fast Growing Asian Companies With High Insider Ownership screener has unearthed 652 more companies for you to explore.Click here to unveil our expertly curated list of 655 Fast Growing Asian Companies With High Insider Ownership.
• Ready For A Different Approach? Uncover 12 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com